Gensaic Announces Collaboration with Novo Nordisk to Unlock Next Generation Precision Therapies

(March 03, 2025) by Novo Nordisk.

Total deal value of up to $354 million in upfront, development, and commercial milestone payments per target plus tiered royalties; Novo Nordisk also will reimburse R&D costs and participate in future financing round

Partnership leverages Gensaic’s proprietary FORGE™ engine for tissue-selective intracellular delivery of therapeutic molecules.